Related Experiment Video
Updated: Aug 16, 2026
11:35
The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study
Celia Oreja-Guevara1,2, Irene Gómez-Estévez3, Laura Agüado García4
1CSUR Multiple Sclerosis, Department of Neurology, Hospital Universitario Clínico San Carlos, IdISCC, Madrid, Spain.
Therapeutic Advances in Neurological Disorders
|August 15, 2026
Summary
Real-world siponimod treatment in active secondary progressive multiple sclerosis (SPMS) showed stabilized disability and reduced disease activity. Most patients maintained stable Expanded Disability Status Scale (EDSS) scores and were relapse-free after one year, with a favorable safety profile.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Limited real-world data exists for siponimod in active secondary progressive multiple sclerosis (SPMS).
- Understanding treatment patterns and outcomes in people with SPMS (pwSPMS) is crucial.
Purpose of the Study:
- To evaluate the real-world effectiveness and safety of siponimod in pwSPMS.
- To assess demographic and clinical characteristics of pwSPMS treated with siponimod.
Main Methods:
- A retrospective, multicenter, observational study involving 210 pwSPMS treated with siponimod.
- Collected clinical, radiological, and laboratory data up to 12 months post-treatment initiation.
- Analyzed Expanded Disability Status Scale (EDSS) scores, relapse rates, and radiological activity.
Main Results:
- After one year, 82.8% of patients showed stable EDSS scores, 94.3% were relapse-free, and 85.7% had no new radiological disease activity.
- The study cohort had high disability (mean EDSS 5.7) and comorbidities; 55.9% were unable to work.
- Adverse events occurred in 46.2%, with 12.4% discontinuing treatment permanently.
Conclusions:
- Siponimod demonstrated effectiveness in stabilizing disability and reducing disease activity in pwSPMS in a real-world setting.
- The treatment showed a favorable safety profile, with most patients maintaining disease control.
- pwSPMS treated with siponimod often present with significant disability and comorbidities prior to treatment.
